ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

Program Description

While chronic myeloid leukemia (CML) often progresses slowly, it can transform into a more aggressive form and makes the disease much harder to treat. The current therapeutic landscape for CML includes use of tyrosine kinase inhibitors (TKIs) but these agents are associated with the development of resistance and toxicities that impact treatment adherence. Overcoming discontinuation rates, ensuring medication adherence, and resolving considerations for treatment selection for frontline TKI therapy must all be considered when managing therapies for patients with CML. Managed care pharmacists are ideally positioned to optimize patient outcomes by addressing these challenges through formulary management and treatment sequencing protocols, providing medication therapy management services, and using their expertise to ensure quality and cost-effective care is provided to patients. This activity will focus on data presented at the 2024 ASH Annual Meeting for the use of TKIs in patients with CML, with particular attention to the real-world implications of TKIs and guideline-directed treatment of CML.

Target audience: Oncology pharmacist and managed care pharmacists

Type of activity: Application
Release date: December 19, 2024
Expiration date: December 19, 2025

Time to complete activity: 1.0 hour

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the therapeutic landscape of available and emerging tyrosine kinase inhibitor (TKI) therapies in managing chronic myeloid leukemia (CML), considering long-term safety and tolerability.
• Analyze recent clinical updates presented at the 2024 ASH Annual Meeting on novel and emerging pharmacotherapeutic approaches utilizing TKIs for the treatment of CML.
• Apply the managed care considerations to appropriately assess and integrate new data to optimize the use of TKIs in the treatment of patients with CML.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-354-H01-P. The activity is available for CE credit through December 19, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Timothy Mok, PharmD, BCPS, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Pfizer

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Jordan Snyder PharmD, BCOP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms

View Slides